Onclarity与Cobas HPV检测在中国女性宫颈癌前病变和癌检测中的临床性能
本研究纳入1122名中国女性,比较Onclarity与Cobas HPV检测对宫颈病变的临床性能。两种检测对HPV16、HPV18及其他12种高危型别一致性良好,≥CIN2灵敏度均为90.5%,<CIN2特异度相似。联合细胞学分流时,Onclarity阴道镜转诊率略低(9.0% vs 11.0%),≥CIN2灵敏度相同(75.0%)。
要点
- Onclarity与Cobas对HPV16、HPV18及12种高危型别一致性良好。
- 两种检测≥CIN2灵敏度均为90.5%,<CIN2特异度相似。
- 联合细胞学分流时Onclarity阴道镜转诊率略低,灵敏度相同。
核心结论
- 在中国女性宫颈病变检测中,Onclarity表现出与Cobas相当的筛查性能和分流效率。
研究设计与样本
- 共纳入1122名女性,采集宫颈脱落细胞置于PreservCyt介质中,分别用Cobas和Onclarity检测。
- 细胞学和组织学分别由中国医学科学院肿瘤医院资深细胞学家和病理学家小组判读。
主要发现
- HPV16一致性极好(kappa=0.91,95%CI:0.85-0.97)。
- 其他12种高危型别一致性极好(kappa=0.84,95%CI:0.78-0.90)。
- HPV18一致性很好(kappa=0.75,95%CI:0.69-0.81)。
- ≥CIN2灵敏度Onclarity和Cobas均为90.5%。
- <CIN2特异度Onclarity为84.2%(95%CI:81.6-86.4),Cobas为80.4%(95%CI:77.6-82.8)。
关键数值与推荐
- 联合细胞学分流时,阴道镜转诊率Onclarity为9.0%,Cobas为11.0%。
- 联合细胞学分流时,≥CIN2灵敏度Onclarity和Cobas均为75.0%(95%CI:53.1-88.8)。
临床怎么用
- Onclarity可作为中国女性宫颈癌筛查的HPV检测选择,性能与Cobas相当。
- 联合细胞学分流时Onclarity可能略微降低阴道镜转诊率而不牺牲灵敏度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Roche Cobas (Cobas) and BD Onclarity (Onclarity) human papillomavirus (HPV) assays are convenient, PCR-based, HPV DNA tests; currently, data on performance of Onclarity in Chinese women is limited. We aimed to evaluate the clinical performance of Onclarity for detecting cervical lesions in Chinese women. METHODS: In total, 1122 women were enrolled into this study. Exfoliated cervical cells were collected in PreservCyt medium and were tested using Cobas and Onclarity. Cytology and histology were interpreted by senior cytologists and a panel of pathologists, respectively, at Cancer Hospital, Chinese Academy of Medical Sciences. RESULTS: The assays showed excellent concordance for HPV16 (kappa = 0.91, 95% CI: 0.85-0.97) and for 12 other high-risk types (HPV31/33/35/39/45/51/52/56/58/59/66/68, kappa = 0.84, 95% CI: 0.78-0.90), and very good concordance for HPV18 (kappa = 0.75, 95% CI: 0.69-0.81). No difference for ≥CIN2 sensitivity was observed between Onclarity and Cobas (both 90.5%); and the <CIN2 specificity for detection was similar between Onclarity (84.2%, 95% CI: 81.6-86.4) and Cobas (80.4%, 95% CI: 77.6-82.8). When combined with cytology triage, the colposcopy referral rate point estimate was slightly lower for Onclarity (9.0%) than for Cobas (11.0%), with the same ≥CIN2 sensitivity of 75.0% (95% CI: 53.1-88.8) for Onclarity and Cobas. CONCLUSIONS: Onclarity exhibited comparable screening performance and triage efficiency compared to Cobas in detection of cervical lesions in Chinese women.
引用
- Li T, Wu Z, Jiang M, et al. Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women. Gynecol Oncol. 2020. PMID: 31964506. doi:10.1016/j.ygyno.2020.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。